Fludarabine
It is a cytotoxic chemo-therapeutic agent.Treatment of patients with B-cell chronic lymphocytic leukaemia (CLL) with sufficient bone marrow reserve and who have not responded to or whose disease has progressed during or after treatment with at least one alkylating agent containing regimen.
Adults : 25mg/m2 body surface given daily for 5 consecutive days in every 28 days by IV route.
Hypersensitivity to this drug or its components. Renally impaired patients (creatinine clearance
When use at high doses fludarabine is associated with blindness, coma and death. Preexisting skin cancer.
Myelo-suppression (neutropenia, thrombocytopenia and anaemia), fever, chills, and infection. Oedema, malaise, fatigue, anorexia, nausea, vomiting, and weakness.
Pentostatin (deoxycoformycin): use of fludarabine in combination with pentostatin is not recommended because of a very high incidence of fatal pulmonary toxicity. Adenosine uptake inhibitors : The therapeutic efficacy of fludarabine may be reduced by dipyridamole and other adenosine uptake inhibitors.
